WILL LIAU ADDRESS ON 10/27/22 AT UPENN WHAT BRIM BROUGHT UP IN THE Q AND A ON 5/10/22 (NYAS MULHOLLAND TLD PRESENTATION ) , WHEN HE SAID, " dr mulholland's team has been looking at radiological markers and we'll present that in june and that will add to the story in terms of using each patient as a control and and having another dimension of efficacy ,.".
one more question yeah i wanted to uh answer david's question um 40:30 and uh congratulate paul holland and the northwest bio team without being 40:36 self-congratulatory my full disclosure i'm one of the 70 authors 40:41 and we've been waiting for uh advanced like this for a long time david in addition to the 40:47 external controls and the numbers um we have some unpublished data from pan 40:53 uh dr mulholland's team has been looking at radiological markers and we'll present that in june and that's obviously uh 41:00 will add to the story uh in terms of using each patient as a control and 41:06 and having uh another dimension of efficacy thank you
Linda Liau speaks at UPENN on 10/27/22. Presumably , she will address at this UPENN conference what Brem said on 5/10/22 was to come out the next month,i.e., June, 2022.
BREM: "uh dr mohan's team has been looking at radiological markers and we'll present that in june and that's obviously uh 41:00 will add to the story uh in terms of using each patient as a control and 41:06 and having uh another dimension of efficacy thank you: .
1)
@alphavestcaphttps://t.co/asL6HnWWPp$nwbo@alphavestcap At NYAS ( 5/10/22) , Brem ( NS-UPENN) alluded to more data coming from their radiological studies , relating to the DC VAX L phase 3 trail data . Please elucidate. THANKS. jhpratt@alphavestcapital.com
Market Data 
Markets 
AI
